Literature DB >> 24652960

Changing myelofibrosis's natural course at last.

Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24652960     DOI： 10.1182/blood-2014-01-551267

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

Review 1.  Ruxolitinib: a review of its use in patients with myelofibrosis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

2.  Disease Modification in Myelofibrosis: An Elusive Goal?

Authors:  Pankit Vachhani; Srdan Verstovsek; Prithviraj Bose
Journal:  J Clin Oncol       Date:  2022-01-27       Impact factor: 44.544

3.  Does angiogenesis matter in primary myelofibrosis?

Authors:  Paulo Vidal Campregher
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.